Indoleamine 2,3-dioxygenase in tumor induced tolerance

被引：18

作者：

Liu Xiao-qian ^{[1
]}

Wang Xin ^{[1
]}

机构：

[1] Shandong Univ, Dept Hematol, Prov Hosp, Jinan 250021, Shandong, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2009年 / 122卷 / 24期

关键词：

indoleamine 2,3-dioxygenase; immune tolerance; dendritic cells; regulatory T cells; 1-methyl-tryptophan; REGULATORY T-CELLS; PLASMACYTOID DENDRITIC CELLS; DRAINING LYMPH-NODES; TRYPTOPHAN CATABOLISM; BACTERIAL LIPOPOLYSACCHARIDE; INCREASED POPULATIONS; PERIPHERAL-BLOOD; IDO; INHIBITION; EXPRESSION;

D O I：

10.3760/cma.j.issn.0366-6999.2009.24.030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To review the recent studies about the role of indoleamine 2,3-dioxygenase (IDO) in tumor induced tolerance. Data sources Published articles (1978-2009) on IDO and tumor induced tolerance were selected from Medline. Study selection Articles selected were relevant to development of IDO in tumor induced tolerance. Of all originally identified articles, 50 specially addressed the stated purpose. Results Recent work has revealed IDO at high levels in tumors and in tumor-draining lymph nodes and a close relationship between IDO activity and the regulatory T cells. Conclusion Up-regulation of IDO is proven to be a mechanism of acquired tolerance in tumors, in which the closely coupled positive feedback system between IDO and regulatory T cells may be considered to play an important role. Chin Med J 2009,122(24):3072-3077

引用

页码：3072 / 3077

页数：6

共 50 条

[21] Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Yong Wha
Hajjar, Joud
Hwu, Patrick
Naing, Aung
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
[22] A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases
Zhou, Qihui
Shi, Yu
Chen, Chao
Wu, Fengtian
Chen, Zhi
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (02)
[23] Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
Ravishankar, Buvana
Liu, Haiyun
Shinde, Rahul
Chandler, Phillip
Baban, Babak
Tanaka, Masato
Munn, David H.
Mellor, Andrew L.
Karlsson, Mikael C. I.
McGaha, Tracy L.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (10) : 3909 - 3914
[24] Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Prendergast, G. C.
Chang, M. Y.
Mandik-Nayak, L.
Metz, R.
Muller, A. J.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (15) : 2257 - 2262
[25] Posttranslational modification of indoleamine 2,3-dioxygenase
Fujigaki, Hidetsugu
Seishima, Mitsuru
Saito, Kuniaki
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2012, 403 (07) : 1777 - 1782
[26] Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase
Metz, Richard
DuHadaway, James B.
Rust, Sonja
Munn, David H.
Muller, Alexander J.
Mautino, Mario
Prendergast, George C.
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) : 1864 - 1871
[27] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Yu
Kato, Shumei
Nesline, Mary K.
Conroy, Jeffrey M.
DePietro, Paul
Pabla, Sarabjot
Kurzrock, Razelle
CANCER TREATMENT REVIEWS, 2022, 110
[28] Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus
Romani, Luigina
Zelante, Teresa
De Luca, Antonella
Bozza, Silvia
Bonifazi, Pierluigi
Moretti, Silvia
D'Angelo, Carmen
Giovannini, Gloria
Bistoni, Francesco
Fallarino, Francesca
Puccetti, Paolo
MEDICAL MYCOLOGY, 2009, 47 : S154 - S161
[29] Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
de Jong, Renske A.
Kema, Ido P.
Boerma, Annemarie
Boezen, H. Marike
van der Want, Johannes J. L.
Gooden, Marloes J. M.
Hollema, Harry
Nijman, Hans W.
GYNECOLOGIC ONCOLOGY, 2012, 126 (03) : 474 - 480
[30] The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, Lieve
Chevolet, Ines
Kruse, Vibeke
EUROPEAN JOURNAL OF CANCER, 2017, 76 : 167 - 182

← 1 2 3 4 5 →